Oral Antibiotics for Cellulitis
Primary Recommendation
For nonpurulent cellulitis (no drainage or abscess), treat with a β-lactam antibiotic targeting streptococci—specifically cephalexin 500 mg four times daily or penicillin—for 5-6 days. 1
Treatment Algorithm by Clinical Presentation
Nonpurulent Cellulitis (No Drainage, No Abscess)
First-line therapy:
- Cephalexin 500 mg four times daily for 5-6 days 1
- Alternative: Dicloxacillin 500 mg four times daily 1
- Alternative: Amoxicillin 875 mg twice daily 1
Duration: 5-6 days is sufficient for patients who can self-monitor with close follow-up 1. The 2021 American College of Physicians guideline specifically recommends this shorter duration over the traditional 10-14 days 1.
When to add MRSA coverage: Only if the patient fails to respond to β-lactam therapy after 48-72 hours, or if systemic toxicity is present at initial evaluation 1. Empirical MRSA coverage is NOT routinely recommended for nonpurulent cellulitis 1, 2.
Purulent Cellulitis (Drainage/Exudate Without Drainable Abscess)
Empirical MRSA coverage is required:
Monotherapy options (cover both MRSA and streptococci):
Combination therapy options:
- TMP-SMX (1-2 double-strength tablets twice daily) PLUS a β-lactam (e.g., amoxicillin 875 mg twice daily) 1
- Doxycycline or minocycline (100 mg twice daily) PLUS a β-lactam 1
Duration: 5-10 days, individualized based on clinical response 1
Important caveat: TMP-SMX and tetracyclines lack reliable streptococcal coverage, necessitating combination with a β-lactam when used for purulent cellulitis 1.
Penicillin Allergy Alternatives
For nonpurulent cellulitis in penicillin-allergic patients:
- Non-immediate hypersensitivity: Cephalexin 500 mg four times daily (cross-reactivity risk <2%) 1
- Immediate hypersensitivity (anaphylaxis history): Clindamycin 300-450 mg three times daily 1
For purulent cellulitis in penicillin-allergic patients:
- Clindamycin 300-450 mg three times daily (covers both MRSA and streptococci) 1
- Linezolid 600 mg twice daily (covers both pathogens) 1
Evidence Reconciliation: The MRSA Coverage Controversy
Key clinical trial findings challenge routine MRSA coverage:
The 2017 JAMA trial by Moran et al. demonstrated that adding TMP-SMX to cephalexin for uncomplicated cellulitis did NOT improve cure rates in the per-protocol analysis (83.5% vs 85.5%, difference -2.0%, 95% CI -9.7% to 5.7%) 3. A 2013 trial by Peterson et al. similarly found no benefit (85% vs 82% cure rates, P=0.66) 4.
However, a 2010 retrospective cohort from Hawaii (high MRSA prevalence area) showed TMP-SMX had significantly higher success rates than cephalexin (91% vs 74%, P<0.001) 5. This geographic variation is critical.
Clinical interpretation: The IDSA guidelines appropriately distinguish between nonpurulent cellulitis (streptococcal, no MRSA coverage needed) and purulent cellulitis (MRSA coverage required) 1. Recent systematic reviews confirm that streptococci cause the vast majority of nonpurulent cellulitis cases 2, 6.
Common Pitfalls to Avoid
Do NOT:
- Use rifampin as monotherapy or adjunctive therapy for cellulitis 1
- Prescribe TMP-SMX or tetracyclines alone for nonpurulent cellulitis (inadequate streptococcal coverage) 1
- Routinely cover MRSA in nonpurulent cellulitis without treatment failure 1, 2
- Use tetracyclines in children <8 years old 1
- Continue antibiotics beyond 5-6 days if clinical improvement is evident 1
Do:
- Reassess at 48-72 hours; if no improvement on β-lactam therapy, add or switch to MRSA-active agent 1
- Consider local MRSA prevalence and resistance patterns when selecting empirical therapy 5
- Obtain cultures from purulent sites when antibiotics are prescribed 1
Pediatric Considerations
Dosing for children:
- Cephalexin: 25-50 mg/kg/day in 3-4 divided doses 1
- Clindamycin: 20-30 mg/kg/day in 3 divided doses (oral) 1
- TMP-SMX: 8-12 mg/kg/day (based on trimethoprim component) in 2 divided doses 1
- Avoid tetracyclines in children <8 years 1
For minor pediatric skin infections (impetigo), topical mupirocin 2% ointment three times daily is appropriate 1.